These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 33446144)
1. Patients with low nicotinamide N-methyltransferase expression benefit significantly from bevacizumab treatment in ovarian cancer. Li J; Yue H; Yu H; Lu X; Xue X BMC Cancer; 2021 Jan; 21(1):67. PubMed ID: 33446144 [TBL] [Abstract][Full Text] [Related]
2. Bevacizumab confers significant improvements in survival for ovarian cancer patients with low miR-25 expression and high miR-142 expression. Li J; Yue H; Li W; Zhu G; Zhu T; Chen R; Lu X J Ovarian Res; 2021 Nov; 14(1):166. PubMed ID: 34802430 [TBL] [Abstract][Full Text] [Related]
3. Nicotinamide N-methyltransferase overexpression may be associated with poor prognosis in ovarian cancer. Harmankaya İ; Akar S; Uğraş S; Güler AH; Ezveci H; Aydoğdu M; Çelik Ç J Obstet Gynaecol; 2021 Feb; 41(2):248-253. PubMed ID: 32285726 [TBL] [Abstract][Full Text] [Related]
4. Nicotinamide N-methyltransferase overexpression is associated with Akt phosphorylation and indicates worse prognosis in patients with nasopharyngeal carcinoma. Win KT; Lee SW; Huang HY; Lin LC; Lin CY; Hsing CH; Chen LT; Li CF Tumour Biol; 2013 Dec; 34(6):3923-31. PubMed ID: 23838801 [TBL] [Abstract][Full Text] [Related]
5. Development and validation of SIRT3-related nomogram predictive of overall survival in patients with serous ovarian cancer. Li J; Yue H; Yu H; Lu X; Xue X J Ovarian Res; 2019 May; 12(1):47. PubMed ID: 31113446 [TBL] [Abstract][Full Text] [Related]
6. High stromal nicotinamide N-methyltransferase (NNMT) indicates poor prognosis in colorectal cancer. Song M; Li Y; Miao M; Zhang F; Yuan H; Cao F; Chang W; Shi H; Song C Cancer Med; 2020 Mar; 9(6):2030-2038. PubMed ID: 31989785 [TBL] [Abstract][Full Text] [Related]
7. Expression profile and prognostic value of NNMT in patients with pancreatic cancer. Xu Y; Liu P; Zheng DH; Wu N; Zhu L; Xing C; Zhu J Oncotarget; 2016 Apr; 7(15):19975-81. PubMed ID: 26942567 [TBL] [Abstract][Full Text] [Related]
9. Accumulation of Nicotinamide N-Methyltransferase (NNMT) in Cancer-associated Fibroblasts: A Potential Prognostic and Predictive Biomarker for Gastric Carcinoma. Zhang L; Song M; Zhang F; Yuan H; Chang W; Yu G; Niu Y J Histochem Cytochem; 2021 Mar; 69(3):165-176. PubMed ID: 33283625 [TBL] [Abstract][Full Text] [Related]
10. Overexpression of Nicotinamide N-methyltransferase mainly covers stroma of colorectal cancer and correlates with unfavorable survival by its product 1-MNA. Yang J; Tong Q; Zhang Y; Yuan S; Gao Y; Deng K; Wang Y; Lu J; Xie X; Zhang Z; Zhang J J Cancer; 2021; 12(20):6170-6181. PubMed ID: 34539890 [No Abstract] [Full Text] [Related]
11. Expression of nicotinamide N-methyltransferase in hepatocellular carcinoma is associated with poor prognosis. Kim J; Hong SJ; Lim EK; Yu YS; Kim SW; Roh JH; Do IG; Joh JW; Kim DS J Exp Clin Cancer Res; 2009 Feb; 28(1):20. PubMed ID: 19216803 [TBL] [Abstract][Full Text] [Related]
12. Nicotinamide N-methyltransferase decreases 5-fluorouracil sensitivity in human esophageal squamous cell carcinoma through metabolic reprogramming and promoting the Warburg effect. Cui Y; Yang D; Wang W; Zhang L; Liu H; Ma S; Guo W; Yao M; Zhang K; Li W; Zhang Y; Guan F Mol Carcinog; 2020 Aug; 59(8):940-954. PubMed ID: 32367570 [TBL] [Abstract][Full Text] [Related]
13. Nicotinamide N-methyltransferase enhances chemoresistance in breast cancer through SIRT1 protein stabilization. Wang Y; Zeng J; Wu W; Xie S; Yu H; Li G; Zhu T; Li F; Lu J; Wang GY; Xie X; Zhang J Breast Cancer Res; 2019 May; 21(1):64. PubMed ID: 31101119 [TBL] [Abstract][Full Text] [Related]
14. Nicotinamide N-methyltransferase expression in squamous cell carcinoma of the vulva. Çelik ZE; Akar S; Fındık S; Aytekin E; Çelik Ç J Obstet Gynaecol; 2022 Aug; 42(6):2325-2330. PubMed ID: 35499473 [TBL] [Abstract][Full Text] [Related]
15. Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer. Secord AA; McCollum M; Davidson BA; Broadwater G; Squatrito R; Havrilesky LJ; Gabel AC; Starr MD; Brady JC; Nixon AB; Duska LR Gynecol Oncol; 2019 Jun; 153(3):555-561. PubMed ID: 30929823 [TBL] [Abstract][Full Text] [Related]
16. Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube cancers: A retrospective review. Roque DM; Ratner ES; Silasi DA; Azodi M; Rutherford TJ; Schwartz PE; Nelson WK; Santin AD Gynecol Oncol; 2015 Jun; 137(3):392-400. PubMed ID: 25792179 [TBL] [Abstract][Full Text] [Related]
17. A Novel Scoring System for Pivotal Autophagy-Related Genes Predicts Outcomes after Chemotherapy in Advanced Ovarian Cancer Patients. Niu Y; Sun W; Chen K; Fu Z; Chen Y; Zhu J; Chen H; Shi Y; Zhang H; Wang L; Shen HM; Xia D; Wu Y Cancer Epidemiol Biomarkers Prev; 2019 Dec; 28(12):2106-2114. PubMed ID: 31533939 [TBL] [Abstract][Full Text] [Related]
18. Nicotinamide N-Methyltransferase in Head and Neck Tumors: A Comprehensive Review. Togni L; Mascitti M; Sartini D; Campagna R; Pozzi V; Salvolini E; Offidani A; Santarelli A; Emanuelli M Biomolecules; 2021 Oct; 11(11):. PubMed ID: 34827592 [TBL] [Abstract][Full Text] [Related]
19. Tumor stromal nicotinamide N-methyltransferase overexpression as a prognostic biomarker for poor clinical outcome in early-stage colorectal cancer. Ogawa M; Tanaka A; Namba K; Shia J; Wang JY; Roehrl MHA Sci Rep; 2022 Feb; 12(1):2767. PubMed ID: 35177765 [TBL] [Abstract][Full Text] [Related]
20. Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology/GOG study. Ferriss JS; Java JJ; Bookman MA; Fleming GF; Monk BJ; Walker JL; Homesley HD; Fowler J; Greer BE; Boente MP; Burger RA Gynecol Oncol; 2015 Oct; 139(1):17-22. PubMed ID: 26216729 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]